Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
A Randomized Study Of The Effect Of Exemestane (Aromasin) Versus Placebo On Breast Density In Postmenopausal Women At Increased Risk For Development Of Breast Cancer
Sponsor: NCIC Clinical Trials Group
A NA clinical study on Breast Cancer, this trial is completed. The trial is conducted by NCIC Clinical Trials Group and has accumulated 8 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
May 2020 — Jan 2021 [monthly]
Completed NA
-
Mar 2020 — May 2020 [monthly]
Completed NA
▶ Show 3 earlier versions
-
Jun 2018 — Mar 2020 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Aug 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NCIC Clinical Trials Group
For direct contact, visit the study record on ClinicalTrials.gov .